331 related articles for article (PubMed ID: 23178324)
1. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.
Naumann M; Dressler D; Hallett M; Jankovic J; Schiavo G; Segal KR; Truong D
Toxicon; 2013 Jun; 67():141-52. PubMed ID: 23178324
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
[TBL] [Abstract][Full Text] [Related]
5. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Naumann M; So Y; Argoff CE; Childers MK; Dykstra DD; Gronseth GS; Jabbari B; Kaufmann HC; Schurch B; Silberstein SD; Simpson DM;
Neurology; 2008 May; 70(19):1707-14. PubMed ID: 18458231
[TBL] [Abstract][Full Text] [Related]
6. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins.
Lakraj AA; Moghimi N; Jabbari B
Toxins (Basel); 2013 Apr; 5(4):821-40. PubMed ID: 23612753
[TBL] [Abstract][Full Text] [Related]
7. Clinical differences between botulinum neurotoxin type A and B.
Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin treatment of secretory disorders.
Naumann M; Jost W
Mov Disord; 2004 Mar; 19 Suppl 8():S137-41. PubMed ID: 15027066
[TBL] [Abstract][Full Text] [Related]
9. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
Chen JJ; Dashtipour K
Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
[TBL] [Abstract][Full Text] [Related]
10. Treatment of palmar hyperhidrosis with botulinum toxin type A: results of a pilot study based on a novel injective approach.
Campanati A; Giuliodori K; Giuliano A; Martina E; Ganzetti G; Marconi B; Chiarici A; Offidani A
Arch Dermatol Res; 2013 Oct; 305(8):691-7. PubMed ID: 23800969
[TBL] [Abstract][Full Text] [Related]
11. Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea.
Hosp C; Naumann MK; Hamm H
Semin Neurol; 2016 Feb; 36(1):20-8. PubMed ID: 26866492
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin for treatment of glandular hypersecretory disorders.
Laing TA; Laing ME; O'Sullivan ST
J Plast Reconstr Aesthet Surg; 2008 Sep; 61(9):1024-8. PubMed ID: 18619934
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-term botulinum toxin treatment for acquired cervical dystonia: a 25-year follow-up.
Petracca M; Lo Monaco MR; Ialongo T; Di Stasio E; Cerbarano ML; Maggi L; De Biase A; Di Lazzaro G; Calabresi P; Bentivoglio AR
J Neurol; 2023 Jan; 270(1):340-347. PubMed ID: 36068376
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study.
Basciani M; Di Rienzo F; Bizzarrini M; Zanchi M; Copetti M; Intiso D
Arch Dermatol Res; 2014 Jul; 306(5):497-503. PubMed ID: 24522897
[TBL] [Abstract][Full Text] [Related]
15. Sialorrhea: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins.
Lakraj AA; Moghimi N; Jabbari B
Toxins (Basel); 2013 May; 5(5):1010-31. PubMed ID: 23698357
[TBL] [Abstract][Full Text] [Related]
16. Botulinum Toxin A and B in sialorrhea: Long-term data and literature overview.
Petracca M; Guidubaldi A; Ricciardi L; Ialongo T; Del Grande A; Mulas D; Di Stasio E; Bentivoglio AR
Toxicon; 2015 Dec; 107(Pt A):129-40. PubMed ID: 26327120
[TBL] [Abstract][Full Text] [Related]
17. A pharmacodynamic comparison study of different botulinum toxin type A preparations.
Kim SB; Ban B; Jung KS; Yang GH
Dermatol Surg; 2013 Jan; 39(1 Pt 2):150-4. PubMed ID: 23301818
[TBL] [Abstract][Full Text] [Related]
18. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Simpson DM; Gracies JM; Graham HK; Miyasaki JM; Naumann M; Russman B; Simpson LL; So Y;
Neurology; 2008 May; 70(19):1691-8. PubMed ID: 18458229
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of different botulinum neurotoxin preparations.
Abrams SB; Hallett M
Toxicon; 2013 Jun; 67():81-6. PubMed ID: 23375537
[TBL] [Abstract][Full Text] [Related]
20. Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials.
Del Sorbo F; Albanese A
Toxicon; 2015 Dec; 107(Pt A):89-97. PubMed ID: 26365917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
